Zhang Xiaodong, Zhang Lei, Wang Hainan
Center for Drug Evaluation, State Food Drug Administration, Beijing 100038, China.
Zhongguo Zhong Yao Za Zhi. 2012 Aug;37(15):2333-7.
To analyze reasons for disapproval of registration application of new traditional Chinese medicines in recent years and discuss potential problems occurring in R&D and registration administration of new traditional Chinese medicines in China.
All applications of new traditional Chinese medicines for registrations that had been disapproved by Center for Drug Evaluation of State Food Drug Administration from 2006 to 2008 were searched in data bank. Specific reasons for disapproval of each variety were inquired and sorted out. The statistics involved the proportion of each type (kind) disapproval reasons in all disapprovals in order to analyze which were the main reasons. The results were analyzed to find out potential problems occurring in R&D and registration administration of new traditional Chinese medicines in China.
There were totally 247 disapproved registration applications for new traditional Chinese medicines. Among them, there were 218 applications for clinical trials and 29 applications for launch in the market There were 9 categories (29 types) of reasons for the applications for clinical trials applications, mainly including such problems as R&D proposal, non-clinical effectiveness and non-clinical safety; while there were 5 categories (9 types) of reasons for the applications for launch in the market, with clinical effectiveness as the main reason.
There were many kinds of reasons for the disapproval registration applications of new traditional Chinese medicines in recent years in China, mainly including such problems as effectiveness, safety and proposal basis. This reflects problems occurring in R&D and registration administration of new traditional Chinese medicines in China to some extent.
分析近年来中药新药注册申请不批准的原因,探讨我国中药新药研发及注册管理中存在的潜在问题。
检索国家食品药品监督管理总局药品审评中心2006年至2008年所有不批准的中药新药注册申请,查询并梳理各品种不批准的具体原因,统计各类不批准原因在所有不批准情况中所占比例,以分析主要原因,通过对结果的分析找出我国中药新药研发及注册管理中存在的潜在问题。
中药新药注册申请不批准的共有247件,其中临床试验申请218件,上市申请29件。临床试验申请的不批准原因有9类(29种),主要包括研发方案、非临床有效性和非临床安全性等问题;上市申请的不批准原因有5类(9种),主要原因是临床有效性。
近年来我国中药新药注册申请不批准的原因多样,主要包括有效性、安全性和申报依据等问题,这在一定程度上反映了我国中药新药研发及注册管理中存在的问题。